IL-12-engineered human PSMA-CAR T cells for the treatment of advanced prostate cancer - PubMed
2 hours ago
- #IL-12 engineering
- #CAR T cells
- #prostate cancer
- Researchers optimized a human scFv-based PSMA-targeted CAR (hPSMA-CAR) for selective targeting.
- They engineered the CAR T cells with membrane-bound IL-12 (mbIL12) to enhance expansion, IFN-γ production, and anti-tumor activity in vitro.
- In two bone-metastatic prostate cancer models, mbIL12-engineered hPSMA-CAR T cells showed potent in vivo anti-tumor responses.
- The study aims to address toxicities like macrophage activation syndrome seen with previous CAR T therapies by using human-derived antigen-binders.
- The developed therapeutic has potential for safe and effective treatment of advanced PSMA+ prostate cancer.